Pharma Major Boehringer Ingelheim India Announces Price Reduction for Jardiance and Glyxambi in India - Video
|
Overview
Pharma major Boehringer Ingelheim has announced a significant price reduction for its popular drugs, JARDIANCE and GLYXAMBI, making them more affordable for patients suffering from Type 2 Diabetes (T2D), Heart Failure (HF), and Chronic Kidney Disease (CKD).
JARDIANCE® a globally recognised SGLT2 inhibitor, has undergone a 31% price reduction, while, GLYXAMBI®, a combination therapy for Type 2 Diabetes management, is now 25% more affordable, benefiting a broader patient population.
Both JARDIANCE® and GLYXAMBI® are original research products having 10 years of experience in India.
JARDIANCE® containing (Empagliflozin) remains the most extensively researched SGLT2 inhibitor in cardio-renal-metabolic medicine, backed by landmark trials and global guideline recommendations.
GLYXAMBI®, a dual therapy containing Empagliflozin + Linagliptin is the world’s first approved SGLT2i + DPP4i combination, delivers powerful efficacy, proven cardiovascular-renal benefits, and the convenience of a once-daily 8mm pill.
These medications have been widely supported by international clinical guidelines, highlighting their role as first-line, evidence-based treatments in modern diabetes care.
Commenting on this development, Rohit Seth, Director - Marketing, CXE, BD, and International Business, and Ashwani Jolly, Director - Sales, from Boehringer Ingelheim India, stated:
"For nearly a decade, Boehringer Ingelheim India has been committed to advancing care for people living with type 2 diabetes mellitus, cardiovascular disease, and chronic kidney disease. We sincerely appreciate your trust and support in bringing these innovations to patients in India."
"In our endeavor to remain patient-centric and customer-focused, we are pleased to announce a 31% price reduction for JARDIANCE® and a 25% price reduction for GLYXAMBI®, ensuring patients receive the same gold standard in SGLT2i therapy."
"The products continue to be manufactured at our global facilities, with end-to-end quality control measures, guided by the international standards of Good Manufacturing Practices. This offers patients the reassurance of the original treatment option."
The Boehringer Ingelheim India further informed that from March 12, 2025, their co-marketing partnerships with Torrent Pharmaceuticals Ltd. and Lupin Ltd. for empagliflozin and its combination would have concluded in India. This would mark the end of the supply of the original empagliflozin manufactured by Boehringer Ingelheim India to these co-marketing partners.
This price reduction marks a major milestone in improving treatment accessibility, ensuring that innovative, research-backed therapies are within reach for more patients in need.
Speakers
Dr. Nandita Mohan
BDS, MDS( Pedodontics and Preventive Dentistry)
Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751